university medical center hamburg-eppendorf
TRANSCRIPT
![Page 1: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/1.jpg)
Targeting the Contact Phase – potential for betteranticoagulants?
Thomas RennéInstitute for Clinical Chemistry and Laboratory Medicine
University Medical Center Hamburg-Eppendorf
![Page 2: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/2.jpg)
The contact pathway
ThrombocytesEndothelial cells Cancer CellsLeukocytes
PKHK
Bradykinin
HKFXII
FXI
B2R
Signalling cascades
Coagulation
FXII
Renné et al, Blood (2018)
ActivatorInflammation
![Page 3: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/3.jpg)
Thromboembolic disease
MI
DVT/PE
stroke
![Page 4: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/4.jpg)
![Page 5: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/5.jpg)
The plasma coagulation system
TF
TFFVII
--
FXII
FXI
Fibrin
Thrombin
ContactInjury
aPTT
5 billionaPTT assays
annually
![Page 6: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/6.jpg)
Ratnoff & Colopy, J Clin Invest (1955)
FXII deficiency - normal haemostasis
John Hageman
![Page 7: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/7.jpg)
TF
TFFVII
FXII
FXI
Fibrin
Thrombin
ContactInjury
FXII has no function in coagulation ?
Naito & Fujikawa, J Biol Chem (1981); Gailani & Broze, Science (1981)
aPTTprolonged
![Page 8: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/8.jpg)
20
40
60
80
aPTT [s]
WT + Heparin
0
300
600
900
1200
> 1200
bleeding time [s]
WT + Heparin
WT FXII-/- FXII-/-
FXII-/- mice have a prolonged aPTT butnormal haemostasis
Pauer et al, Thromb Haemost (2004)
WT
![Page 9: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/9.jpg)
Renné et al, J Exp Med (2005); Kleinschnitz et al, J Exp Med (2006)
Defective thrombosis in FXII-/-micewild-type
FXII-/-
![Page 10: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/10.jpg)
0
20
40
60
*
FXI-/-wt
isch
emic
volu
me
[mm
3 ]
FXI-/-wt FXII-/-
+ + +- - -
fibrin
Impaired pathological fibrin formation in FXI-/-mice
fibrin GP Ib merge
![Page 11: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/11.jpg)
Targeting FXII activity
![Page 12: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/12.jpg)
Antibody 3F7 (3F12) selectively blocks FXII activity
![Page 13: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/13.jpg)
ECMO: Extra Corporeal Membrane Oxygenation
Highly thrombogenic
Needs anticoagulation
![Page 14: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/14.jpg)
![Page 15: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/15.jpg)
Targeting FXIIa provides thromboprotection in ECMO
Saline
3F7
Heparin
D Pressure[mm Hg]
![Page 16: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/16.jpg)
Larsson et al, Science Trans Med (2014)
Heparin
Bleeding timeskin [sec]
Blood losscuticle [ml/10 min]
300
600
NaCl0
3F7
2,5
5,0
0HeparinNaCl 3F7
Targeting FXII activity does not interfere with haemostasis
![Page 17: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/17.jpg)
Targeting FXII in baboons and FXI activity in rabbitsprotects against thrombosis sparing hemostasis
David et al, Science Transl Med (2016)Matafonov et al, Blood (2014)
![Page 18: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/18.jpg)
Effect of FXI-ASO on the Coagulation System.
Büller et al, N Engl J Med (2014)
FXI knockdown using ASO provides safe anticoagulationin patients after knee surgery
![Page 19: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/19.jpg)
Thrombosis
Maas & Renné, Blood (2018)
HaemostasisBleeding
Thrombus
Sealing ofwounds
FXII-drivencoagulation
Revision of the classical coagulation balance
![Page 20: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/20.jpg)
FXII-driven coagulation in thrombosis
Haemostasis Thombosis
Kenne et al, J Int Med (2015)
![Page 21: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/21.jpg)
FXII-/-WT
accelerated clotting time [x-fold]
4
3
2
platelet activator +-+-
5
Castaldi et al, Nature (1965); Walsh & Griffin, Blood (1981); Johne et al, BC (2006); Bäck et al, BBRC (2010)
Activated platelet-driven coagulation is defective inFXII-deficient plasma
![Page 22: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/22.jpg)
• glass• silica• dextran sulfate• kaolin
• DNA/RNA• collagen• lipopolysaccaride• glycosaminoglycans
artificial natural
FXII contact activators
Maas et al, Sem Thromb Hemost (2011)
![Page 23: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/23.jpg)
throm
bin
+
+ p
hosp
hatas
e
[bp]
2550
100200
w/o trap6
throm
bin
Platelet polyphosphate (polyP)
Müller, Mutch et al, Cell (2009)
![Page 24: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/24.jpg)
Platelet polyP initiates FXII-driven coagulation
thrombin [nM]200
100
FVIIai + polyP
0 10 20 30 40time [min]
+ 4.8 µg/ml
+ 1.2 µg/ml
w/o
FXII-def.0
thrombin
TF FVIIa
FVIIai/ASISFXIIa
FXIa
Müller, Mutch et al, Cell (2009)
![Page 25: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/25.jpg)
2/15 10/1513/15
WT WT +PGE1
FXII-/-
FXII-/-mice are protected from polyP- and activated platelet-driven thrombosis
Purified platelet polyP Activated platelets
![Page 26: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/26.jpg)
Inherited deficiency in platelet polyP protectsIp6K1-/-mice from thrombosis
Gosh et al, Blood (2013)
![Page 27: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/27.jpg)
Platelet polyP promotes thrombosis
Modified from Caen & Wu, J Thromb Haemost (2010)Walker et al, Br J Haematol (2007)
n
![Page 28: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/28.jpg)
Activated platelets release polyP into the supernatant…
Labberton et al, Nat Commun (2016)
polyP[nM Pi/108 platelets]
![Page 29: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/29.jpg)
…however the majority of polyP is retained at the platelet surface
Labberton et al, Nat Commun (2016)
polyP[nM Pi/108 platelets]
![Page 30: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/30.jpg)
Insoluble polyP on platelet surfaces
Verhoef et al, Blood (2017)
polyPExtracellular polyPTotal polyP
polyP
Wijeyewickrema et al, Blood (2016)
polyP
![Page 31: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/31.jpg)
solublesupernatant
insolublecell surface
Platelets have two pools of polyP: long chain/insoluble and short chain/soluble polymers
Verhoef et al, Blood (2017)
![Page 32: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/32.jpg)
Platelet polyP form Ca2+-rich microparticles
DensityVerhoef et al, Blood (2017)
Chain-lengthindependent
![Page 33: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/33.jpg)
Disassembly of platelet polyP microparticles impairstheir FXII activating potential
+EDTA
Surface-associated(insoluble)
Verhoef et al, Blood (2017)
soluble
FXII
activ
ity
![Page 34: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/34.jpg)
Platelet-derived polyP microparticles drive thrombosisin a FXII-dependent manner
Nickel et al., ATVB (2017)
Hemostasis Thrombosis
![Page 35: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/35.jpg)
Analysis of polyP nanoparticles on platelet surfaces
Labberton et al, Flow Cytometry (2017)
![Page 36: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/36.jpg)
Targeting the polyP/contact pathway in
cancer-associated thrombosis
![Page 37: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/37.jpg)
Prostate cancer exposes polyP that activates FXII
polyP
FXIIa
overlay
+ Ph
osph
atas
eProstate cancer
polyP
Fibrin
Cancer patient plasmacells MP tissue
Nickel et al, Blood (2015)
![Page 38: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/38.jpg)
Targeting FXII interferes with prostate cancer-triggered PE
![Page 39: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/39.jpg)
The polyP/contact pathway contributes to thrombosis in cancer
Nickel et al, Thromb Res (2016)
![Page 40: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/40.jpg)
Targeting polyP
![Page 41: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/41.jpg)
Degradation of polyP ablates their procoagulat activity
E. coli exopolyphosphatase(PPX)
![Page 42: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/42.jpg)
Targeting polyP blocks procoagulant platelet activity
FXII-/-WT
accelerated clotting time [x-fold]
3
2
1
platelet activator + ++-
4
WT +PPX
Labberton et al, Nat Commun (2016)
![Page 43: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/43.jpg)
Targeting polyP interferes with platelet-driven thrombosis without affecting hemostasis
Labberton et al, Nat Commun (2016)
![Page 44: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/44.jpg)
Regulation of platelet polyP
Pi polyP
![Page 45: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/45.jpg)
Systems biology identified XPR1 as the majorPi exporter in platelets
Mailer, Allend et al, (in revision 2020)
![Page 46: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/46.jpg)
Platelet Xenotropic and polytropic retrovirus receptor 1 (XPR1)
Merge
XPR1
Bright field
Mailer, Allende et al, BLOOD (2020)
Pi
intracellular
extracellular
SPX
PDZbm
N
C
Receptordomain
retrovirus
![Page 47: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/47.jpg)
Subcellular localization of XPR1 in platelets
![Page 48: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/48.jpg)
XPR1 expression inversely regulates polyP in cellsMeg01HEK293
XPR1
40
pCHIX-XPR1 (μg)
84210.5Mock
70
MW(kDa)
VASP
Mock
70
2 4 8 16 32
pCHIX-XPR1 (μg)
40
XPR1
VASP
Mw(kDa)
overexpression
Knock-down
![Page 49: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/49.jpg)
Pharmacology: Recombinant XPR1 inhibitors
XVDL
259XLV-Env
1
6xHis RBD
TM
554478
CT
644
RBD
PRL
Mw(kDa)
35
25
40
PVDL XVDL XVDLPVDLPRL
35
25
40
Mw(kDa)
PVDL
262PLV-Env
1
6xHis RBD
TM
620439
CT
641
RBD
Mailer, Allende et al, BLOOD (2020)
active inhibitor inactive control
![Page 50: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/50.jpg)
Inhibition of XPR1 increases soluble and insoluble polyP
soluble
insoluble
total
![Page 51: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/51.jpg)
Targeting XPR1 increases procoagulant platelet activity
![Page 52: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/52.jpg)
Targeting XPR1 increases thrombosis under flow
PPX 0 2 20 200 PPX 0 2 20 200
arterial venous
![Page 53: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/53.jpg)
Targeting XPR1 increases coagulation and platelet polyP
Fibrin GPIb MergeBright field
0XV
DL
(μg/
ml)
Fibrin GPIb MergeBright field
020
0
0XV
DL
μg/m
l 020
0
polyPBright fieldpolyPBright field
200
200
XVD
L (μ
g/m
l)XV
DL
(μg/
ml)
arterial venous
![Page 54: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/54.jpg)
Platelet-specific ablation of XPR1 in mice
Platelet XPR1 knockout PolyP[mM Pi/108 pl]
MW(kDa)70 XPR1
Platelets
43 β-actin
Xpr1fl/fl Xpr1fl/fl
Pf4-CreXpr1fl/+
Pf4-Cre
Mailer, Allende et al, BLOOD (2020)
![Page 55: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/55.jpg)
Increased arterial occlusion in platelet XPR deficient mice
![Page 56: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/56.jpg)
Increased platelet-driven venous thrombosis but normal haemostasis in platelet XPR1-deficient mice
![Page 57: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/57.jpg)
XPR1 regulates procoagulant platelet polyP
Graphical abstract of Mailer, Allende et al, BLOOD (2020)
![Page 58: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/58.jpg)
Factor XII as a target for treatment of thrombosis
§ FXII contact activation is essential for thrombosis but FXII is dispensable for haemostasis
§ PolyP is an in vivo FXII contact activator triggers the „intrinsic“ coagulation pathway on platelets and cancer cell surfaces in vivo
§ PolyP forms insoluble Ca2+-rich microparticles that activate FXII in vivoindependently of the chain length of the individual poly
§ Targeting polyP or FXII (or FXI) provides safe thromboprotection(“Safe Anticoagulants“) and provides additional anti-inflammatory activities
§ The Pi exporter XPR1 regulates polyP in platelets (and other cells) suggesting that Pi have a role in thrombosis
![Page 59: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/59.jpg)
Clément Naudin
MarcoHeestermans
• Lynn Butler, Tromsø• Christian Drouet, Grenoble• Tobias Fuchs, Hamburg• Dave Gailani, Nashville• Johan Heemskerk, Maastricht• Christoph Kleinschnitz, Essen• Nigel Key, Chapell Hill• Florian Langer, Hamburg• Nigel Mackman, Chapell Hill• Joost Meijers, Amsterdam• James Morrissey, Ann Arbor• Werner Müller-Esterl, Frankfurt• Nicola Mutch, Aberdeen
Jenny Björkqvist Coen Maas
Anna Sala
Thank you very very much!• Gunnar Nielsson, Stockholm• Benhard Nieswandt, Würzburg• Markus Noethen, Bonn• Kosta Panousis, Melbourne• Klaus Preissner, Giessen• Huge ten Cate, Mastricht• Albert Sickmann, Dortmund• Alvin Schmaier, Cleveland• Henri Spronk, Maastricht• Evi Stavrou, Cleveland• Guido Stoll, Würzburg• Ulrich Walter, Mainz• Walter Wuillemin, Luzern
Katrin Nickel
![Page 60: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/60.jpg)
Special thank to the people who did the work!
Mikel AllendeLinda Labberton Katrin NickelReiner Mailer
![Page 61: University Medical Center Hamburg-Eppendorf](https://reader031.vdocuments.net/reader031/viewer/2022013005/61cc8a5dd0d2bb7e9d7117e5/html5/thumbnails/61.jpg)